Actuate Therapeutics(ACTU.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Actuate Therapeutics
ACTU.US
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company’s lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as metastatic melanoma and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc.
1.883 T
ACTU.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Actuate Therapeutics, Inc. (ACTU) Receives a Buy from Craig-Hallum

    Craig-Hallum analyst Albert Lowe has maintained a Buy rating on Actuate Therapeutics, Inc. (ACTU) with a price target of $25.00. Lowe, a 4-star analyst with an 8.0% average return, also covers other healthcare stocks. Additionally, H.C. Wainwright reiterated a Buy rating on ACTU with a $20.00 price target.

    Tip Ranks·
    US
    ACTU
    -2.28%
    Tip Ranks·
    US
    ACTU
    -2.28%

    Actuate Therapeutics reports positive Phase 2 pancreatic cancer data

    Actuate Therapeutics, Inc. (ACTU) announced positive results from its Phase 2 Actuate-1801 trial for metastatic pancreatic cancer, showing that elraglusib combined with chemotherapy improved median overall survival to 10.1 months compared to 7.2 months for chemotherapy alone. The trial involved 286 patients across 60 sites and met its primary endpoint, demonstrating a 38% reduction in death risk. Safety profiles were comparable, and ongoing analyses suggest potential predictive biomarkers. Analysts rate ACTU stock as a Buy with a $20.00 price target, highlighting the company's focus on innovative cancer therapies.

    Tip Ranks·
    US
    ACTU
    -2.28%
    Tip Ranks·
    US
    ACTU
    -2.28%

    Actuate Therapeutics Reports Phase 2 Trial Success for Elraglusib in Metastatic Pancreatic Cancer

    Actuate Therapeutics Inc. reported successful Phase 2 trial results for elraglusib in metastatic pancreatic cancer, presented at the 2026 ASCO GI Symposium. The trial met its primary endpoint, showing a 38% reduction in death risk compared to standard chemotherapy, with improved overall survival. As of November 2025, 17 patients in the elraglusib group remain alive, including three who have exceeded 24 months of survival, while no patients on chemotherapy alone are alive.

    Reuters·
    US
    ACTU
    -2.28%
    Reuters·
    US
    ACTU
    -2.28%

    Insider at Actuate Therapeutics Makes a Major Move With Fresh Stock Sale

    Insider Todd Thomson sold 280,000 shares of Actuate Therapeutics, Inc. (ACTU) for $1.624 million on January 7, 2026, raising investor interest. The company recently reported promising Phase 1 pediatric data for its lead candidate, elraglusib, in treating Ewing sarcoma and neuroblastoma, which may enhance its regulatory prospects. Additionally, Phase II data for elraglusib in advanced salivary gland cancers showed favorable survival outcomes, potentially leading analysts to reassess the stock's market outlook. ACTU's year-to-date price performance is 8.82%, with a market cap of $147.4 million.

    Tip Ranks·
    US
    ACTU
    -2.28%
    Tip Ranks·
    US
    ACTU
    -2.28%

    Actuate Therapeutics Director Todd Thomson Reports Disposal of Common Shares

    Todd S. Thomson, Director and 10% Owner of Actuate Therapeutics Inc., reported the disposal of common shares of the company. The full filing is accessible via the provided link. This news brief was generated by Public Technologies and is for informational purposes only, not to be considered as financial, investment, or legal advice. Actuate Therapeutics Inc. is responsible for the original content published through EDGAR on January 07, 2026.

    Reuters·
    US
    ACTU
    -2.28%
    Reuters·
    US
    ACTU
    -2.28%
    © 2026 Longbridge｜Disclaimer